Drugs that contain Glecaprevir; Pibrentasvir

1. Drug name - MAVYRET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8648037 ABBVIE INC Macrocyclic proline derived HCV serine protease inhibitors
Jan, 2032

(9 years from now)

US8937150 ABBVIE INC Anti-viral compounds
May, 2032

(9 years from now)

USRE48923 ABBVIE INC Crystal forms
May, 2035

(12 years from now)

US9321807 ABBVIE INC Crystal forms
Jun, 2035

(12 years from now)

CN103819537A ABBVIE INC Anti-Viral Compounds
May, 2017

(5 years ago)

CN104193729A ABBVIE INC Antiviral Compound
Sep, 2017

(5 years ago)

CN106986861A ABBVIE INC Antiviral Compound
Jun, 2020

(2 years ago)

CN103819459B ABBVIE INC Antiviral Compound
May, 2021

(1 year, 4 months ago)

CN103819459A ABBVIE INC Antiviral Compound
May, 2021

(1 year, 4 months ago)

CN103172620A ABBVIE INC Antiviral Composition
Jun, 2030

(7 years from now)

CN103172620B ABBVIE INC Antiviral Compound
Jun, 2030

(7 years from now)

CN102333772A ABBVIE INC Anti-Viral Compounds
Jun, 2030

(7 years from now)

CN102333772B ABBVIE INC Antiviral Composition
Jun, 2030

(7 years from now)

CN103209686A ABBVIE INC Solid Composition
Jun, 2031

(8 years from now)

CN103209686B ABBVIE INC Solid Composition
Jun, 2031

(8 years from now)

CN103209703A ABBVIE INC Macrocyclic Proline Derived Hcv Serine Protease Inhibitors
Sep, 2031

(8 years from now)

CN104829688A ABBVIE INC Macrocyclic Proline Derived Hcv Serine Protease Inhibitors
Sep, 2031

(8 years from now)

CN104829688B ABBVIE INC Macrocyclic Proline-Derived Hcv Serine Protease Inhibitors
Sep, 2031

(8 years from now)

CN103209703B ABBVIE INC Macrocyclic Proline Derived Hcv Serine Protease Inhibitors
Sep, 2031

(8 years from now)

CN103153988B ABBVIE INC Antiviral Compound
Oct, 2031

(9 years from now)

CN103153988A ABBVIE INC Anti-Viral Compounds
Oct, 2031

(9 years from now)

CN103354808A ABBVIE INC Antiviral Compound
Dec, 2031

(9 years from now)

CN103354808B ABBVIE INC Antiviral Compound
Dec, 2031

(9 years from now)

CN103596941A ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

CN103596941B ABBVIE INC Antiviral Compounds
Feb, 2032

(9 years from now)

CN108350016A ABBVIE INC Antiviral Tetrahydrofuran Derivatives
Sep, 2036

(13 years from now)

CN108350016B ABBVIE INC Antiviral Tetrahydrofuran Derivatives
Sep, 2036

(13 years from now)

EP2954892B1 ABBVIE INC Solid Compositions
Jun, 2020

(2 years ago)

EP2954892A1 ABBVIE INC Solid Compositions
Jun, 2020

(2 years ago)

EP2455376A1 ABBVIE INC Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv)
Jun, 2030

(7 years from now)

EP2337781B1 ABBVIE INC Anti-Viral Compounds To Treat Hcv Infection
Jun, 2030

(7 years from now)

EP2628481B1 ABBVIE INC Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv
Jun, 2030

(7 years from now)

EP2628481A1 ABBVIE INC Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv
Jun, 2030

(7 years from now)

EP2337781A2 ABBVIE INC Anti-Viral Compounds To Treat Hcv Infection
Jun, 2030

(7 years from now)

EP2455376B1 ABBVIE INC Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv)
Jun, 2030

(7 years from now)

EP2368890B1 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2368890A1 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2368890B9 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2579854B1 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2579854B2 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2579854A1 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2618831B1 ABBVIE INC Macrocyclic Proline Derived Hcv Serine Protease Inhibitors
Sep, 2031

(8 years from now)

EP2618831A1 ABBVIE INC Macrocyclic Proline Derived Hcv Serine Protease Inhibitors
Sep, 2031

(8 years from now)

EP2618831A4 ABBVIE INC Macrocyclic Proline Derived Hcv Serine Protease Inhibitors
Sep, 2031

(8 years from now)

EP2692346A1 ABBVIE INC An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative
Oct, 2031

(9 years from now)

EP2692346B1 ABBVIE INC An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative
Oct, 2031

(9 years from now)

EP2678334B1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

EP2678334A1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028937 ABBVIE INC Anti-viral compounds Jun, 2030

(7 years from now)

US10039754 ABBVIE INC Anti-viral compounds Jun, 2030

(7 years from now)

US9586978 ABBVIE INC Anti-viral compounds Nov, 2030

(8 years from now)

US10028937

(Pediatric)

ABBVIE INC Anti-viral compounds Dec, 2030

(8 years from now)

US10039754

(Pediatric)

ABBVIE INC Anti-viral compounds Dec, 2030

(8 years from now)

US9586978

(Pediatric)

ABBVIE INC Anti-viral compounds May, 2031

(8 years from now)

US8648037

(Pediatric)

ABBVIE INC Macrocyclic proline derived HCV serine protease inhibitors Jul, 2032

(9 years from now)

US8937150

(Pediatric)

ABBVIE INC Anti-viral compounds Nov, 2032

(10 years from now)

US10286029 ABBVIE INC Method for treating HCV Mar, 2034

(11 years from now)

US10286029

(Pediatric)

ABBVIE INC Method for treating HCV Sep, 2034

(11 years from now)

USRE48923

(Pediatric)

ABBVIE INC Crystal forms Nov, 2035

(13 years from now)

US9321807

(Pediatric)

ABBVIE INC Crystal forms Dec, 2035

(13 years from now)

US11246866 ABBVIE INC Solid pharmaceutical compositions for treating HCV Jun, 2036

(13 years from now)

US11246866

(Pediatric)

ABBVIE INC Solid pharmaceutical compositions for treating HCV Dec, 2036

(14 years from now)

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg

Dosage: PELLETS;ORAL

More Information on Dosage
Strength Dosage Availability
50MG;20MG/PACKET PELLETS;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.